Retatrutide, CJC-1295 and Ipamorelin: What the Studies Actually Tested
Compare the human studies of retatrutide, CJC-1295 and ipamorelin, and the evidence missing for their proposed combination.
FormBlends Editorial Research · Updated 2026-10-02
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
Was this three-peptide combination tested?
The publications linked here studied the substances separately. None tested retatrutide plus CJC-1295 plus ipamorelin as a combined intervention. They cannot establish that adding growth-hormone secretagogues preserves muscle, increases fat loss or improves tolerability during retatrutide treatment.
Three different research questions
| Substance | Participants and endpoint | What the study does not answer |
|---|---|---|
| CJC-1295 | Healthy adults; growth hormone and IGF-I concentrations over short studies | Muscle preservation or additional fat loss during retatrutide treatment |
| Ipamorelin | Patients recovering from bowel surgery; time to tolerate a solid meal | Long-term body composition in people using a weight-loss medicine |
| Retatrutide | Obesity trials; bodyweight outcomes in assigned study groups | Outcomes with CJC-1295 and ipamorelin added |
What the CJC-1295 result means
The 2006 randomized studies lasted 28 and 49 days. They measured hormone exposure in healthy adults. An increase in IGF-I is a biomarker result; it is not a measurement of retained skeletal muscle during substantial weight loss. The long-acting CJC-1295 formulation studied also cannot be assumed interchangeable with every product advertised under that name.
What the ipamorelin result means
The 2014 postoperative study enrolled 117 people. Its key and secondary efficacy analyses did not find statistically significant differences from placebo. A study of gastrointestinal recovery after surgery offers no direct test of a retatrutide weight-loss combination.
What would resolve the combination question?
A useful comparison would randomize participants to retatrutide alone or the defined combination and measure lean mass, strength, fat mass and adverse events. Measuring bodyweight alone would not distinguish loss of fat from loss of lean tissue. Until such a comparison is available, a claim about muscle preservation needs a study of that actual outcome and combination, not three separate mechanisms.